A new review (Journal of Alzheimer's Disease) outlines a three-stage classification of the impact of COVID-19 on the central nervous system and recommends hospitalized patients with the virus all undergo MRI to flag potential neurologic damage and inform postdischarge monitoring.
During the current COVID-19 pandemic, the infection risk for each individual is determining their ability to work, interact with their partners, children and parents. Many of us have changed our treatment practices for MS and related diseases out of fear of a potentially lethal infection, but what do we know about the risk of infection in a patient...
Heat headaches are unlikely to result from the heat itself.
A new clinical research study by Dr. Marjan Rafiee and Dr. Taufik Valiante of the Krembil Brain Institute at Toronto Western Hospital, part of University Health Network, has found that a Mozart composition may reduce seizure frequency in patients with epilepsy.
Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS).
The US Food and Drug Administration (FDA) has approved fenfluramine (Fintepla, Zogenix) oral solution, a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in children age 2 years and older.
Combining four of five healthy lifestyle choices has been linked to up to a 60% reduced risk for Alzheimer dementia in new research that strengthens ties between healthy behaviors and lower dementia risk.(Neurology. Published online June 17, 2020. Abstract)
High adherence to a Mediterranean Diet is associated with reduced incidence and mortality of acute ischemic stroke (AIS) but may also be associated with severity.
Hypertension is associated with significantly increased mortality in patients with COVID-19, new research shows.
Patients who took amlodipine as part of an antihypertensive regimen experienced significantly fewer strokes over two decades, new long-term results from the ASCOT study show. This group showed an 18% decrease in stroke incidence compared with others taking an atenolol-based regimen.
